Risk factors for early- and late-onset infectious complications after CAR T-cell therapy. (A) ORs (univariate analysis) for early- and late-onset infectious complications for (i) the overall cohort receiving either CAR T-cell therapy and (ii) the anti-CD19 CAR T-cell cohort. Whiskers indicate 5th to 95th percentile. (Bi) CAR expansion at day 30 in the MM and DLBCL cohort (t test; mean, 3.53 vs 11.97; P = .009). Whiskers indicate 5th to 95th percentile. (Bii) CAR expansion in patients with DLBCL depending on infectious events within the first 30 days (t test; mean, 3.73 vs 12.58; P = .02).